Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

Multiple receptor tyrosine kinases (RTKs), including PDGFR, have been validated as therapeutic targets in glioblastoma multiforme (GBM), yet inhibitors of RTKs have had limited clinical success. As various antiapoptotic mechanisms render GBM cells resistant to chemo- and radiotherapy, we hypothesized that these antiapoptotic mechanisms also confer resistance to RTK inhibition. We found that in vitro inhibition of PDGFR in human GBM cells initiated the intrinsic pathway of apoptosis, as evidenced by mitochondrial outer membrane permeabilization, but downstream caspase activation was blocked by inhibitor of apoptosis proteins (IAPs). Consistent with this, inhibition of PDGFR combined with small molecule inactivation of IAPs induced apoptosis in human GBM cells in vitro and had synergistic antitumor effects in orthotopic mouse models of GBM and in primary human GBM neurospheres. These results demonstrate that concomitant inhibition of IAPs can overcome resistance to RTK inhibitors in human malignant GBM cells, and suggest that blockade of IAPs has the potential to improve treatment outcomes in patients with GBM.

[1]  A. Kung,et al.  Anti-apoptosis mechanisms in malignant gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Sellers,et al.  A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. , 2007, Cancer research.

[3]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[4]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[5]  Lee M Ellis,et al.  Targeted therapy trials: approval strategies, target validation, or helping patients? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Hongye Liu,et al.  Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.

[7]  M. Berens,et al.  Molecular targets of glioma invasion , 2007, Cellular and Molecular Life Sciences.

[8]  N. Munshi,et al.  Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). , 2004, Blood.

[9]  A. Kung Practices and pitfalls of mouse cancer models in drug discovery. , 2007, Advances in cancer research.

[10]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[11]  C. Dominici,et al.  Increased sensitivity to the platelet‐derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF‐BB‐mediated signaling and STI571‐induced Akt inactivation , 2006, Journal of cellular physiology.

[12]  D. Bodurka,et al.  Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. , 2006, Gynecologic oncology.

[13]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[14]  D. Bigner,et al.  Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[16]  Ning Lin,et al.  Noninvasive Bioluminescence Imaging of Luciferase Expressing Intracranial U87 Xenografts: Correlation with Magnetic Resonance Imaging Determined Tumor Volume and Longitudinal Use in Assessing Tumor Growth and Antiangiogenic Treatment Effect , 2006, Neurosurgery.

[17]  E. Kohmura,et al.  Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines , 2006, Journal of Neuro-Oncology.

[18]  S. Fulda,et al.  Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. , 2005, Cancer research.

[19]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[20]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[21]  C. Duckett,et al.  Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. , 2005, The Journal of clinical investigation.

[22]  T. Mikkelsen,et al.  Angiogenesis and apoptosis in glioma: Two arenas for promising new therapies , 2005, Journal of cellular biochemistry.

[23]  M. Decamp,et al.  The Role of Surgery in N2 Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[24]  F. McCormick,et al.  Killing time for cancer cells , 2005, Nature Reviews Cancer.

[25]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[26]  J. Pollard,et al.  ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance , 2005, Cell Death and Differentiation.

[27]  M. Crow,et al.  Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei , 2005, FEBS letters.

[28]  D. Graves,et al.  FOXO1 Functions as a Master Switch That Regulates Gene Expression Necessary for Tumor Necrosis Factor-induced Fibroblast Apoptosis* , 2005, Journal of Biological Chemistry.

[29]  R. Kiss,et al.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[31]  L. Ellis,et al.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[33]  M. Weller,et al.  Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications , 2004, Journal of Neuro-Oncology.

[34]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[35]  M. Crow,et al.  Apoptosis Repressor with Caspase Recruitment Domain Protects against Cell Death by Interfering with Bax Activation* , 2004, Journal of Biological Chemistry.

[36]  A. Gajjar,et al.  Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. , 2004, The oncologist.

[37]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[38]  D. Matei,et al.  Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation , 2004, Clinical Cancer Research.

[39]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  W. Roa,et al.  X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. , 2003, Clinical and investigative medicine. Medecine clinique et experimentale.

[42]  D. Jo,et al.  Down‐regulation of ARC contributes to vulnerability of hippocampal neurons to ischemia/hypoxia , 2003, FEBS Letters.

[43]  R. Jenkins,et al.  Recent advances in the molecular genetics of primary gliomas , 2003, Current opinion in oncology.

[44]  G. Gores,et al.  Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.

[45]  A. Chakravarti,et al.  The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. , 2002, Cancer research.

[46]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[48]  P. Black,et al.  Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.

[49]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[51]  A. Schally,et al.  Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. , 2000, Neoplasia.

[52]  John Calvin Reed,et al.  Purification and use of recombinant inhibitor of apoptosis proteins as caspase inhibitors. , 2000, Methods in enzymology.

[53]  D. Groothuis,et al.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.

[54]  T. Tsuruo,et al.  A human IAP-family gene, apollon, expressed in human brain cancer cells. , 1999, Biochemical and biophysical research communications.

[55]  A. Merlo,et al.  Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.

[56]  S. Kügler,et al.  Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma , 1999, Cell Death and Differentiation.

[57]  S. Chen,et al.  ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Guha,et al.  Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.

[59]  S. Shamah,et al.  Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells , 1993, Molecular and cellular biology.

[60]  E. Oldfield,et al.  Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.

[61]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[62]  S. Gammeltoft,et al.  Expression of two types of receptor for insulin-like growth factors in human malignant glioma. , 1988, Cancer research.